Onyx Pharmaceuticals, Inc. (ONXX) Bidding Wars: Who Would Be the Best Suitor?
Recently, Amgen, Inc. (NASDAQ:AMGN) made a surprisingly low offer to acquire the pharmaceutical company Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX).
Posts Tagged ‘NASDAQ:ONXX’
Immunomedics, Inc. (IMMU), ImmunoGen, Inc. (IMGN): Should You Invest in These Cancer Treatment Biotechs?
Today, cancer is the second leading cause of death in the United States, accounting for nearly a quarter of all deaths in the country.
Quiksilver, Inc. (ZQK), Pfizer Inc. (PFE): Tuesday’s Top Upgrades (and Downgrades)
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on.
Onyx Pharmaceuticals, Inc. (ONXX) Says the Price Isn’t Right
That's the message from Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) over the weekend after Amgen, Inc. (NASDAQ:AMGN) made an unsolicited offer to buy the company.
United Technologies Corporation (UTX), Travelers Companies Inc (TRV): Will These Unlikely Winners Keep Leading the Dow Higher?
After a strong performance during the first half of the year, the Dow Jones Industrials added to its 2013 gains with a 65-point gain.
Medivation Inc (MDVN), Onyx Pharmaceuticals, Inc. (ONXX): Biotechs Take a Dive After a Standout Start to 2013
Are investors hitting the brakes on biotech? The biotech sector's one of the most boom-or-bust areas for investors, where fortunes can be won or lost.
Onyx Pharmaceuticals, Inc. (ONXX), Arena Pharmaceuticals, Inc. (ARNA): The Top 5 Diseases Caused by Obesity
In the "Global Burden of Disease" report from the World Health Organization, which was compiled over a 20-year period from 1990 through 2010 using data from 500 researchers from...
Revlimid Gains, Celgene Corporation (CELG) Loses
Celgene Corporation (NASDAQ:CELG) announced good news today about its blockbuster drug Revlimid. Did the stock jump as a result? Nope. Shares actually fell by more than 4%.
Onyx Pharmaceuticals, Inc. (ONXX), NewLink Genetics Corp (NLNK): Two Diversified Biotechs to Watch After Impressive ASCO Data
Big Pharma gets the headlines at ASCO, but smaller up-and-coming biotechnology companies also produce breakthroughs in the treatment of cancer.
Celgene Corporation (CELG) at ASCO: Ho-Hum, Ho-Hum, and Hmmm
Celgene Corporation (NASDAQ:CELG) was one of several companies presenting at the American Society of Clinical Oncology, or ASCO, annual meeting in Chicago this week.
ImmunoGen, Inc. (IMGN), AEterna Zentaris Inc. (USA) (AEZS) – Tackling Cancer: Your Best Investing Ideas
Over the past three months, we've taken a deep dive into the 12 cancer types most likely to be diagnosed in the U.S.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): The 7 Most Obese U.S. States
The U.S., which ranks as the most obese nation in the world according to the Organization for Economic Cooperation and Development, has seen a relatively steady increase over ...
Novartis AG (ADR) (NVS), Alexion Pharmaceuticals, Inc. (ALXN), Celgene Corporation (CELG), Onyx Pharmaceuticals, Inc. (ONXX): 4 Companies Riding the Orphan Drug Rocket
A recent report by EvaluatePharma claims that sales of orphan drugs -- ones that target rare diseases -- will grow at twice the rate of the overall prescription market.
Onyx Pharmaceuticals, Inc. (ONXX): Are Hedge Funds Right About This Stock?
Is Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) the right investment to pursue these days? Prominent investors are betting on the stock.
Pfizer Inc. (PFE), Sanofi SA (ADR) (SNY), Onyx Pharmaceuticals, Inc. (ONXX): Will ASCO Unlock Big Value in This Cancer Drug Class?
Avastin -- which the Food and Drug Administration has approved to treat metastatic colorectal cancer (as a first-line and second-line treatment), metastatic HER2-negative breast...
NVIDIA Corporation (NVDA), Onyx Pharmaceuticals, Inc. (ONXX): Three Things That Caught My Attention Last Week
As we enter the heart of second-quarter earnings reports, I can't help but point out that the majority we've covered over the past year have been better than expected.
Onyx Pharmaceuticals, Inc. (ONXX), Pfizer Inc. (PFE), And Kidney Cancer’s Top Bets
As I noted nine weeks ago, cancer statistics are both staggering and disappointing.
Why AVEO Pharmaceuticals, Inc. (AVEO) Fell
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Raptor Pharmaceutical Corp. (RPTP), AVEO Pharmaceuticals, Inc. (AVEO) & Two FDA Decisions You Can’t Afford to Miss This Week
Last week we focused on five can't-miss earnings reports.
AstraZeneca plc (ADR) (AZN), Exelixis, Inc. (EXEL), Pfizer Inc. (PFE) & Tackling Cancer: Thyroid Cancer’s Biggest Current and Upcoming Players
As I noted eight weeks ago, cancer statistics are both staggering and disappointing.
Onyx Pharmaceuticals, Inc. (ONXX), Cyberonics, Inc. (CYBX) Among Elite Investor’s Top Five Positions
To say that William Leland Edwards of Palo Alto Investors invest heavily in healthcare stocks would be, well, a bit of an understatement. The fund’s positions read like a ...
Onyx Pharmaceuticals, Inc. (ONXX), Johnson & Johnson (JNJ): Is Celgene Corporation (CELG)’s Pipeline a Fit for Your Portfolio?
Few big biotech firms have been as successful recently as Celgene Corporation (NASDAQ:CELG).
Amarin Corporation plc (ADR) (AMRN), Antares Pharma Inc (ATRS): 3 FDA Decisions You Need to Watch in 2013
Sequester or no sequester, the folks at the Food and Drug Administration look to be quite busy in 2013.
Hedge Funds Are Selling Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX)
Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) was in 24 hedge funds' portfolio at the end of December.
Tackling Cancer: Breast Cancer’s Biggest Current & Upcoming Players – Roche Holding Ltd. (ADR) (RHHBY), AstraZeneca plc (ADR) (AZN), ImmunoGen, Inc. (IMGN)
As I noted two weeks ago, cancer statistics are both staggering and disappointing.
It’s Time for AstraZeneca plc (ADR) (AZN) to Save Its Future
The hits keep coming at AstraZeneca plc (ADR) (NYSE:AZN).
5 Can’t-Miss Health-Care Events This Week: Zogenix, Inc. (ZGNX), Ariad Pharmaceuticals, Inc. (ARIA)
Normally we have a nice blend of health-care events to take notice of each week.
More Upside on this Biotechnology Giant: Celgene Corporation (CELG)
The Food and Drug Administration added Celgene Corporation (NASDAQ:CELG)’s Pomalyst to the list of approved drugs last Friday.
Pomalyst Takes the Stage: Celgene Corporation (CELG), Johnson & Johnson (JNJ), Onyx Pharmaceuticals, Inc. (ONXX)
Its parent has one of the longest and varied histories in the annals of medicine. Its sibling is a star raking in billions of dollars every year.
Celgene Corporation (CELG)’s Fastest-Growing Drug
What's the fastest growing drug in Celgene Corporation (NASDAQ:CELG)'s portfolio? It isn't Revlimid, Vidaza, or Abraxane.
This Just In: Upgrades and Downgrades – Dendreon Corporation (DNDN) and More
At The Motley Fool, we poke plenty of fun at Wall Street analysts and their endless cycle of upgrades, downgrades, and "initiating coverage at neutral." Today, we'll show you ...
Can Johnson & Johnson (JNJ) Hold Its Ground in the Multiple Myeloma Market?
Johnson & Johnson (NYSE:JNJ) may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market leading therapeutic...
What’s Next for Sarepta Therapeutics Inc (SRPT)?
What's next for Sarepta Therapeutics Inc (NASDAQ:SRPT) ? After announcing encouraging results last October from a phase 2b study of eteplirsen targeting treatment of Duchenne...
More Good News for Celgene Corporation (CELG)
As expected, the U.S. Food and Drug Administration granted approval on Feb. 8 for Celgene Corporation (NASDAQ:CELG)'s Pomalyst in treating patients with multiple myeloma.
Celgene Corporation (CELG): Still Revving Up With Revlimid
What a roll Celgene Corporation (NASDAQ:CELG) has been on lately. The company has experienced success after success in recent months.
